LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU=Khiew Stella H.
  2. AU="Hamedi, Homa"
  3. AU="De Yoreo, James J"
  4. AU="Von Feldt, Joan M"
  5. AU="Collins, Jorja"
  6. AU="Jaffe, D A"
  7. AU="Li, Hehe"
  8. AU=McClain Micah T
  9. AU=Feitosa Gilson
  10. AU="Ficara, Elena"
  11. AU=Choi KeunOh
  12. AU="van Driel, Mieke L"
  13. AU="Guzmán, María Camila"
  14. AU="Tom Van Den Bogaert"
  15. AU="Di Gioia, Mariacarla"
  16. AU=Hassan Omar F
  17. AU="Rose, Dale"
  18. AU="Baba, Satoshi"
  19. AU=Orienti Isabella
  20. AU="Ragasa, Catherine"
  21. AU="Sadrzadeh, S M Hossein"
  22. AU=Celedon Vera
  23. AU="Ravins Dohare"
  24. AU="Köcher, Thomas"
  25. AU="Iyengar, Sudha K"
  26. AU="Dimitroulis, Ioannis"
  27. AU="García Sandoval, Blanca"
  28. AU="Yuchio Yanagawa"
  29. AU="Ben Warne"
  30. AU="Freitas, Bruna Andrade Santos"
  31. AU="Behar, Raquel"
  32. AU="Hakimi, Mathew"
  33. AU="Voigt, C"
  34. AU="Harenberg, Job"
  35. AU="Bradfield, Owen"
  36. AU=Parmegiani Lodovico
  37. AU=Nasmyth Kim AU=Nasmyth Kim
  38. AU=Krumm Brian AU=Krumm Brian
  39. AU="Isojima, Tsuyoshi"
  40. AU="Rioufol, Gilles"
  41. AU="Hiesmayr, B. C."
  42. AU="Qudrat-Ullah, Hassan"
  43. AU=Kim Ginah Lee
  44. AU="Jeannin, Anne-Caroline"

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: MHC Tetramers Specifically Identify High- and Low-avidity Donor-specific B Cells in Transplantation Tolerance and Rejection.

    Durgam, Samarth S / Khiew, Stella H W / Sayin, Ismail / Jain, Dharmendra / Yin, Dengping / Cavazzoni, Cecilia B / Sage, Peter T / King, R Glenn / Chong, Anita S

    Transplantation

    2023  Volume 107, Issue 12, Page(s) 2526–2532

    Abstract: Background: Although donor-specific antibody pre- and posttransplantation is routinely assessed, accurate quantification of memory alloreactive B cells that mediate recall antibody response remains challenging. Major histocompatibility complex (MHC) ... ...

    Abstract Background: Although donor-specific antibody pre- and posttransplantation is routinely assessed, accurate quantification of memory alloreactive B cells that mediate recall antibody response remains challenging. Major histocompatibility complex (MHC) tetramers have been used to identify alloreactive B cells in mice and humans, but the specificity of this approach has not been rigorously assessed.
    Methods: B-cell receptors from MHC tetramer-binding single B cells were expressed as mouse recombinant immunoglobulin G1 (rIgG1) monoclonal antibodies, and the specificity was assessed with a multiplex bead assay. Relative binding avidity of rIgG1 was measured by modified dilution series technique and surface plasmon resonance. Additionally, immunoglobulin heavy chain variable regions of 50 individual B-cell receptors were sequenced to analyze the rate of somatic hypermutation.
    Results: The multiplex bead assay confirmed that expressed rIgG1 monoclonal antibodies were preferentially bound to bait MHC class II I-E d over control I-A d and I-A b tetramers. Furthermore, the dissociation constant 50 binding avidities of the rIgG1 ranged from 10 mM to 7 nM. The majority of tetramer-binding B cells were low avidity, and ~12.8% to 15.2% from naive and tolerant mice and 30.9% from acute rejecting mice were higher avidity (dissociation constant 50 <1 mM).
    Conclusions: Collectively, these studies demonstrate that donor MHC tetramers, under stringent binding conditions with decoy self-MHC tetramers, can specifically identify a broad repertoire of donor-specific B cells under conditions of rejection and tolerance.
    MeSH term(s) Humans ; Mice ; Animals ; Transplantation Tolerance ; Major Histocompatibility Complex ; Histocompatibility Antigens Class II ; Immunoglobulin G ; Antibodies, Monoclonal ; Receptors, Antigen, B-Cell
    Chemical Substances Histocompatibility Antigens Class II ; Immunoglobulin G ; Antibodies, Monoclonal ; Receptors, Antigen, B-Cell
    Language English
    Publishing date 2023-11-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 208424-7
    ISSN 1534-6080 ; 0041-1337
    ISSN (online) 1534-6080
    ISSN 0041-1337
    DOI 10.1097/TP.0000000000004702
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice.

    Young, James S / Khiew, Stella H-W / Yang, Jinghui / Vannier, Augustin / Yin, Dengping / Sciammas, Roger / Alegre, Maria-Luisa / Chong, Anita S

    Frontiers in immunology

    2017  Volume 8, Page(s) 1169

    Abstract: Clinical observations that kidney transplant recipients receiving belatacept who experienced T cell-mediated acute rejection can be successfully treated and subsequently maintained on belatacept-based immunosuppression suggest that belatacept is able to ... ...

    Abstract Clinical observations that kidney transplant recipients receiving belatacept who experienced T cell-mediated acute rejection can be successfully treated and subsequently maintained on belatacept-based immunosuppression suggest that belatacept is able to control memory T cells. We recently reported that treatment with CTLA4-Ig from day 6 posttransplantation successfully rescues allografts from acute rejection in a BALB/c to C57BL/6 heart transplant model, in part, by abolishing B cell germinal centers and reducing alloantibody titers. Here, we show that CTLA4-Ig is additionally able to inhibit established T cell responses independently of B cells. CTLA4-Ig inhibited the
    Language English
    Publishing date 2017-09-20
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2606827-8
    ISSN 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2017.01169
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: CSF-1 in Inflammatory and Arthritic Pain Development.

    Saleh, Reem / Lee, Ming-Chin / Khiew, Stella H / Louis, Cynthia / Fleetwood, Andrew J / Achuthan, Adrian / Förster, Irmgard / Cook, Andrew D / Hamilton, John A

    Journal of immunology (Baltimore, Md. : 1950)

    2018  Volume 201, Issue 7, Page(s) 2042–2053

    Abstract: Pain is one of the most debilitating symptoms in many diseases for which there is inadequate management and understanding. CSF-1, also known as M-CSF, acts via its receptor (CSF-1R, c-Fms) to regulate the development of the monocyte/macrophage lineage ... ...

    Abstract Pain is one of the most debilitating symptoms in many diseases for which there is inadequate management and understanding. CSF-1, also known as M-CSF, acts via its receptor (CSF-1R, c-Fms) to regulate the development of the monocyte/macrophage lineage and to act locally in tissues to control macrophage numbers and function. It has been implicated in the control of neuropathic pain via a central action on microglia. We report in this study that systemic administration of a neutralizing anti-CSF-1R or CSF-1 mAb inhibits the development of inflammatory pain induced by zymosan, GM-CSF, and TNF in mice. This approach also prevented but did not ameliorate the development of arthritic pain and optimal disease driven by the three stimuli in mice, suggesting that CSF-1 may only be relevant when the driving inflammatory insults in tissues are acute and/or periodic. Systemic CSF-1 administration rapidly induced pain and enhanced the arthritis in an inflamed mouse joint, albeit via a different pathway(s) from that used by systemic GM-CSF and TNF. It is concluded that CSF-1 can function peripherally during the generation of inflammatory pain and hence may be a target for such pain and associated disease, including when the clinically important cytokines, TNF and GM-CSF, are involved. Our findings have ramifications for the selection and design of anti-CSF-1R/CSF-1 trials.
    MeSH term(s) Animals ; Antibodies, Neutralizing/administration & dosage ; Arthritis, Experimental/immunology ; Arthritis, Rheumatoid/immunology ; Cell Differentiation ; Cell Lineage ; Humans ; Inflammation/immunology ; Joints/immunology ; Macrophage Colony-Stimulating Factor/immunology ; Macrophage Colony-Stimulating Factor/metabolism ; Macrophages/physiology ; Mice ; Mice, Inbred C57BL ; Monocytes/physiology ; Pain ; Receptor, Macrophage Colony-Stimulating Factor/immunology ; Receptor, Macrophage Colony-Stimulating Factor/metabolism ; Signal Transduction
    Chemical Substances Antibodies, Neutralizing ; Macrophage Colony-Stimulating Factor (81627-83-0) ; Receptor, Macrophage Colony-Stimulating Factor (EC 2.7.10.1)
    Language English
    Publishing date 2018-08-17
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3056-9
    ISSN 1550-6606 ; 0022-1767 ; 1048-3233 ; 1047-7381
    ISSN (online) 1550-6606
    ISSN 0022-1767 ; 1048-3233 ; 1047-7381
    DOI 10.4049/jimmunol.1800665
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: CTLA4-Ig in combination with FTY720 promotes allograft survival in sensitized recipients.

    Khiew, Stella H / Yang, Jinghui / Young, James S / Chen, Jianjun / Wang, Qiang / Yin, Dengping / Vu, Vinh / Miller, Michelle L / Sciammas, Roger / Alegre, Maria-Luisa / Chong, Anita S

    JCI insight

    2017  Volume 2, Issue 9

    Abstract: Despite recent evidence of improved graft outcomes and safety, the high incidence of early acute cellular rejection with belatacept, a high-affinity CTLA4-Ig, has limited its use in clinical transplantation. Here we define how the incomplete control of ... ...

    Abstract Despite recent evidence of improved graft outcomes and safety, the high incidence of early acute cellular rejection with belatacept, a high-affinity CTLA4-Ig, has limited its use in clinical transplantation. Here we define how the incomplete control of endogenous donor-reactive memory T cells results in belatacept-resistant rejection in an experimental model of BALB/c.2W-OVA donor heart transplantation into C57BL/6 recipients presensitized to donor splenocytes. These sensitized mice harbored modestly elevated numbers of endogenous donor-specific memory T cells and alloantibodies compared with naive recipients. Continuous CTLA4-Ig treatment was unexpectedly efficacious at inhibiting endogenous graft-reactive T cell expansion but was unable to inhibit late CD4+ and CD8+ T cell infiltration into the allografts, and rejection was observed in 50% of recipients by day 35 after transplantation. When CTLA4-Ig was combined with the sphingosine 1-phosphate receptor-1 (S1PR1) functional antagonist FTY720, alloantibody production was inhibited and donor-specific IFN-γ-producing T cells were reduced to levels approaching nonsensitized tolerant recipients. Late T cell recruitment into the graft was also restrained, and graft survival improved with this combination therapy. These observations suggest that a rational strategy consisting of inhibiting memory T cell expansion and trafficking into the allograft with CTLA4-Ig and FTY720 can promote allograft survival in allosensitized recipients.
    Language English
    Publishing date 2017-05-04
    Publishing country United States
    Document type Journal Article
    ISSN 2379-3708
    ISSN (online) 2379-3708
    DOI 10.1172/jci.insight.92033
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top